Roche Holding AGROP
▲ PositiveRegulationrelevance
FDA approval for Elecsys pTau217 blood test and expanded HER2 tests.
Impact on assets 2
Health Care
Roche Holding AGBiotech & Genomic Medicine
Roper Technologies IncROP
Mentioned
Theme Impact 1
Off-coverage companies
Related news
United States▲impact 4
GRAIL's Galleri Wins Favorable FDA Panel Vote After Strong PATHFINDER 2 Data
GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.
About megatrends
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Regulation
GRAL · Regulation · Positive FDA advisory committee favorable vote supports Galleri's safety and effectiveness, advancing toward potential PMA approval.
GRAL · Technology · Positive PATHFINDER 2 data showed Galleri increased cancers detected six-fold with low false positives and accurate origin identification.
United StatesBillionToOne Fair Value Rises to US$128.57 as Analysts Weigh Reimbursement Risk
BillionToOne's Fair Value estimate has been raised to US$128.57 from US$122.14 in the Simply Wall St framework, as analysts weigh the company's sequencing technology against new reimbursement concerns. Guggenheim lifted its price target on the diagnostics company to US$128 from US$125 ahead of Q3 reporting, while Canaccord initiated coverage with a US$120 target, citing BillionToOne's single molecule next generation sequencing and quantitative counting template technologies as difficult for peers to copy. On the bearish side, Jefferies flagged that the preliminary 2027 CMS clinical laboratory fee schedule points to cuts of up to 15% annually through 2029 for various tests, and noted BillionToOne could see reimbursement pressure on its fetal antigen test, with noninvasive prenatal testing described in the CMS proposal as a more vulnerable application. The framework's revenue growth assumption was trimmed to 26.52% from 28.21%, while profit margin edged up to 15.84% from 15.58%, the future P/E fell to 64.33x from 72.21x, and the discount rate rose to 7.236% from 7.108%.
About megatrends
Biotech & Genomic Medicine › Diagnostics & Precision Testing Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Regulation
Biotech & Genomic Medicine › Life-Science Tools & Sequencing Regulation
BLLN · Capital · Neutral Fair value raised to US$128.57 and Guggenheim/Canaccord price targets lifted on its sequencing technology, but Jefferies flags up to 15% annual CMS reimbursement cuts pressuring its fetal antigen test.
BLLN · Regulation · Negative Preliminary 2027 CMS clinical laboratory fee schedule points to cuts of up to 15% annually through 2029, creating reimbursement pressure on BillionToOne's tests.
United StatesMyriad Genetics Jumps 5% After Craig-Hallum Raises Price Target to $8
Myriad Genetics shares jumped 5% in the afternoon session after Craig-Hallum analyst John Wilkin raised the firm's price target on the stock to $8, according to StreetInsider. The higher price target reflects an increased valuation estimate for the genetic testing company. The move comes after a volatile stretch for the stock, which has seen 44 moves greater than 5% over the last year. Two months ago, Myriad Genetics dropped 46.1% after reporting disappointing second-quarter 2026 results that missed Wall Street's expectations and included a reduced full-year forecast, with revenue of $190.7 million, down 10.5% year-over-year, and an adjusted loss per share of $0.25. The company also slashed its full-year revenue guidance to a midpoint of $780 million, a decrease of over 10% from its previous forecast. Myriad Genetics is down 30.5% since the beginning of the year, and at $4.27 per share, it is trading 47.9% below its 52-week high of $8.18 from November 2025.
About megatrends
Biotech & Genomic Medicine › Diagnostics & Precision Testing Capital
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Capital